(-0.68%) 5 081.51 points
(-0.80%) 38 080 points
(-0.80%) 15 855 points
(-0.73%) $82.03
(0.34%) $2.04
(-2.06%) $2 309.10
(-3.56%) $26.68
(-2.04%) $941.90
(0.35%) $0.936
(0.86%) $11.08
(0.35%) $0.799
(0.31%) $93.59
Live Chart Being Loaded With Signals
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders...
Stats | |
---|---|
Šios dienos apimtis | 303 484 |
Vidutinė apimtis | 142 922 |
Rinkos kapitalizacija | 116.44M |
EPS | $-0.460 ( 2023-11-08 ) |
Last Dividend | $1.512 ( 2023-10-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.563 |
ATR14 | $0.122 (4.49%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-13 | Siegall Clay B | Buy | 20 000 | Stock Option (Right to Buy) |
2023-12-13 | Siegall Clay B | Buy | 0 | |
2023-11-17 | Kulkarni Sandeep Chidambar | Buy | 4 000 | Common Stock |
2023-11-17 | Thiara Parvinder | Buy | 1 000 | Common Stock |
2023-10-27 | Castelein Caley | Buy | 15 800 | Common Stock |
INSIDER POWER |
---|
83.81 |
Last 89 transactions |
Buy: 5 796 448 | Sell: 603 108 |
Tūris Koreliacija
Talaris Therapeutics, Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
MRNS | 0.86 |
NPCE | 0.842 |
ALR | 0.818 |
SMED | 0.817 |
EPZM | 0.815 |
BIS | 0.808 |
THRY | 0.807 |
LTRY | 0.807 |
CNCE | 0.805 |
LVO | 0.802 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
WTBA | -0.867 |
EGAN | -0.854 |
ABST | -0.853 |
CRNT | -0.851 |
BNIXU | -0.85 |
PIXY | -0.834 |
CNDT | -0.832 |
FREQ | -0.823 |
VWE | -0.817 |
UPC | -0.813 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Talaris Therapeutics, Koreliacija - Valiuta/Žaliavos
Talaris Therapeutics, Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-16.66 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-16.66 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.26 |
FY | 2020 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.070 |
Financial Reports:
No articles found.
Talaris Therapeutics, Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$1.512 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $1.512 | 2023-10-19 |
Last Dividend | $1.512 | 2023-10-19 |
Next Dividend | $0 | N/A |
Payout Date | 2023-10-20 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $1.512 | -- |
Avg. Dividend % Per Year | 46.23% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $1.512 | 138.70% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.382 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.364 | 1.500 | -5.16 | -7.74 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 18.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 18.14 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 8.28 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00420 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -17.91 | 1.000 | -7.75 | -7.75 | [3 - 30] |
operatingCashFlowPerShareTTM | -12.28 | 2.00 | -4.09 | -8.19 | [0 - 30] |
freeCashFlowPerShareTTM | -12.47 | 2.00 | -6.24 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00444 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -82.75 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -1.667 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.202 | 1.000 | -0.121 | 0 | [1 - 100] |
returnOnEquityTTM | -0.364 | 2.50 | -3.32 | -7.74 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -12.47 | 2.00 | -4.16 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 55.58 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -12.28 | 2.00 | -4.09 | -8.19 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.00392 | 1.500 | -3.36 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -2.25 |
Talaris Therapeutics,
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.